The significant cardiac and renal protective characteristics of SGLT2 inhibitors have resulted in their widespread use as monotherapy or adjunctive therapy with metformin, sulfonylureas, glucagon-like peptide-1 receptor agonists, thiazolidinediones, and insulin for the management of T2DM, as well as HF with reduced and preserved ejection fraction, as suggested by recent guidelines [109,110,111]. The gene discussed is GLP1R; the disease is hydrops fetalis.